Aratana Therapeutics Inc. (PETX) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) Comparison side by side

Aratana Therapeutics Inc. (NASDAQ:PETX) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aratana Therapeutics Inc. 35.41M 5.11 14.72M -0.51 0.00
OHR Pharmaceutical Inc. N/A 0.00 9.98M -3.54 0.00

In table 1 we can see Aratana Therapeutics Inc. and OHR Pharmaceutical Inc.’s gross revenue, earnings per share and valuation.


Table 2 shows Aratana Therapeutics Inc. and OHR Pharmaceutical Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Aratana Therapeutics Inc. -41.57% -23% -16.1%
OHR Pharmaceutical Inc. 0.00% -71.5% -66.8%

Risk & Volatility

A beta of 1.38 shows that Aratana Therapeutics Inc. is 38.00% more volatile than Standard & Poor’s 500. OHR Pharmaceutical Inc.’s 1.17 beta is the reason why it is 17.00% more volatile than Standard & Poor’s 500.


The Current Ratio of Aratana Therapeutics Inc. is 3.2 while its Quick Ratio stands at 2.7. The Current Ratio of rival OHR Pharmaceutical Inc. is 5.4 and its Quick Ratio is has 5.4. OHR Pharmaceutical Inc. is better equipped to clear short and long-term obligations than Aratana Therapeutics Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Aratana Therapeutics Inc. and OHR Pharmaceutical Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aratana Therapeutics Inc. 0 2 1 2.33
OHR Pharmaceutical Inc. 0 0 0 0.00

The upside potential is 34.41% for Aratana Therapeutics Inc. with average target price of $5.

Insider and Institutional Ownership

Aratana Therapeutics Inc. and OHR Pharmaceutical Inc. has shares held by institutional investors as follows: 69.1% and 12.7%. Insiders held 2.5% of Aratana Therapeutics Inc. shares. Comparatively, OHR Pharmaceutical Inc. has 8.89% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aratana Therapeutics Inc. -3.6% -9.26% -39.09% -23.43% 3.08% -34.42%
OHR Pharmaceutical Inc. 3.29% -17.91% -31.21% -43.18% -50.81% 27.91%

For the past year Aratana Therapeutics Inc. has -34.42% weaker performance while OHR Pharmaceutical Inc. has 27.91% stronger performance.


Aratana Therapeutics Inc. beats on 6 of the 10 factors OHR Pharmaceutical Inc.

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE for appetite stimulation in dogs; and NOCITA, a post-operative anesthetic for cranial cruciate ligament surgery in dogs. The company is also developing AT-002 for evaluating capromorelin for weight management in cats with chronic kidney disease; AT-003, a bupivacaine liposome injectable suspension for post-operative pain management in cats; AT-006, an anti-viral for the treatment of feline herpes virus-induced ophthalmic conditions for cats; AT-016, an adipose-derived allogeneic stem cell therapeutic candidate for the treatment of osteoarthritis pain in dogs; and AT-018, an oral CRTH2 antagonist for the potential treatment of atopic dermatitis in dogs. In addition, the companyÂ’s licensed products include BLONTRESS, a canonized monoclonal antibody for the treatment of B-cell lymphoma in dogs; and TACTRESS, a canonized monoclonal antibody for the treatment of T-cell lymphoma in dogs, as well as AT-014, a novel her2/neu-directed cancer immunotherapy for the treatment of canine osteosarcoma for dogs. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.